Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

28.98 -1.02 (-3.40%)
Streaming Delayed Price Updated: 10:16 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
News headline image
Analyst Expectations for Genmab's Future ↗
 
Via Benzinga
News headline image
Why Shares of Zai Lab Limited Were Jumping on Tuesday ↗
Zai Lab's shares benefited from positive clinical trial news. 
Via The Motley Fool
News headline image
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications ↗
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on... 
Via Benzinga
News headline image
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
From Seagen Inc.
Via Business Wire
News headline image
Analyst Expectations for Genmab's Future ↗
 
Via Benzinga
News headline image
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via Business Wire
News headline image
The 3 Most Promising Biotech Stocks to Own Now ↗
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023 ↗
 
Via Benzinga
News headline image
12 Analysts Have This to Say About Genmab ↗
 
Via Benzinga
News headline image
Where Genmab Stands With Analysts ↗
 
Via Benzinga
News headline image
Is AbbVie Still a Good Dividend Stock to Buy? ↗
Find out if AbbVie can overcome sinking sales of its top-selling product. 
Via The Motley Fool
News headline image
3 Things About Johnson & Johnson Every Smart Investor Knows ↗
The company has been a strong value stock but faces big changes this year. 
Via The Motley Fool
News headline image
3 Biotech Stocks You Better Be Buying on Each and Every Dip ↗
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there. 
Via InvestorPlace
News headline image
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
Expert Ratings for Genmab ↗
 
Via Benzinga
News headline image
Recap: Genmab Q1 Earnings ↗
 
Via Benzinga
News headline image
How To Attend Genmab Q1 2023 Earnings Conference Call ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Genmab ↗
 
Via Benzinga
News headline image
Analyst Ratings for Genmab ↗
 
Via Benzinga
News headline image
3 Biotech Stocks That AI is Loving in July ↗
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential. 
Via InvestorPlace
News headline image
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators? ↗
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer. 
Via The Motley Fool
News headline image
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients ↗
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab... 
Via Benzinga
News headline image
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab
Via Business Wire
News headline image
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
From Genmab
Via Business Wire
News headline image
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
From Genmab
Via Business Wire
News headline image
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
News headline image
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients ↗
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)... 
Via Benzinga
News headline image
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst ↗
 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.